Biotech, Food & Drug

HB Ad Slot
HB Mobile Ad Slot

In today’s hyper-aware environment, concerns about food and drug safety are paramount for both companies and consumers.  The Food and Drug Administration (FDA) and the US Department of Agriculture (USDA) regulates the areas of biotech, food, and drug law. Additionally, laws including the 21st Century Cures Act, and cGMP (Current Good Manufacturing Processes), regulate industry standards/norms in food, cosmetics, and other industry-sectors. Visitors to the National Law Review will find the latest analysis of news, legislation, and upcoming cases/litigation as it relates to this area of law.

With researchers searching for new energy solutions and other developments in biotech, visitors to the NLR will have the opportunity to read content surrounding biosimilars, natural fuel production, medical devices, biotechnology, nanotechnology and materials, and the pharmaceuticals industry. Additionally, content relating to food and drug laws, limits on chemical use in cosmetic products, and other general health/safety topics are covered by the National Law Review and are updated regularly. Additionally, food safety and imports to the United States are also discussed as they become relevant. 

In addition to general health, science, and food/drug, the industry is also closely related to many of the issues related to intellectual property law. New applications for patents, intellectual property, licensing laws, and other areas which are governed by the PTAB court, often crossover into the industry.

New developments in legislation, including the legalization of recreational marijuana has created a new area ripe for legal analysis.  Regulations on how recreational marijuana can be advertised and marketed, distributed and the kind of insurance coverage necessary for dispensaries.  Additionally, employer drug-testing and marijuana statutes have been a hot area of litigation covered by the National Law Review.  

General practices in marketing standards, compliance of federal and state laws/legislation, licensing collaborations, and news related to bringing new products to the market, in the US and abroad, are among the areas visitors to NLR will read about daily. Drug pricing, changes in production standards, regulatory compliance, food safety and handling, drug laws (legalization of marijuana, both recreational and medicinal in the workplace), and labeling and nutritional requirements, are among the many topics covered by the National Law Review daily.

Visitors will always find the latest, up-to-date, most comprehensive coverage on the site. And, news and stories which affect the US, companies which are regulated in the industry, and multinational/international companies, are detailed regularly for NLR readers.

National Law Review Cannabis TwitterFor hourly updates on the latest news about biotech, food & drug, and cannabis laws, regulations, and legislation, be sure to follow our Cannabis X (formerly Twitter) feed, and sign up for complimentary e-news bulletins.

Recent Biotechnology, Food & Drug Administration FDA News

Title
Publication Date Organization Sort descending
Apr
10
2020
COVID-19: DEA and SAMHSA Guidance for Treating Opioid Use Disorders via Telehealth
Jan
17
2017
Massachusetts Has Legalized Marijuana — Should Your Workplace Policies Go Up in Smoke?
Jul
2
2018
Health Care Policy Newsletter: June 25-29, 2018
Dec
23
2021
Vaping Will Not Make You Well
Feb
10
2016
FDA Unveils Action Plan to Combat Opioid Abuse
Jul
23
2018
Health Care Policy Newsletter July 16, 2018
Feb
14
2022
Top Trends in Tech-Enabled Home Care
Apr
8
2019
Bashful Bladders Bring Problems for Employers
Mar
11
2015
Regulation of Chemicals in Consumer Products on the Rise
Aug
26
2015
Kyle Bass Loses Round 1 Of IPR Attack Against Pharma/Biotech Patents
Aug
6
2020
Telehealth and Substance Use Disorder Treatment: State Law Issues
May
1
2018
How The Fanapt Product Label Established Infringement Of Personalized Treatment Claims
Jul
16
2018
Health Care Policy Newsletter: Week of July 9, 2018
Dec
28
2021
FDA Issues Latest Draft Guidance on the Use of Real-World Data and Evidence to Support Regulatory Decision-Making for Drug and Biological Products
Mar
20
2019
An Artful Deal? Critics Question Administration’s Prescription Drug Negotiation Tools for Medicare Advantage
Sep
19
2022
New California Bill Protects Employees’ Off-Duty Marijuana Use
Mar
1
2023
North Carolina Senate Passes Compassionate Care Act – at Exactly 4:20 p.m.
May
9
2017
Are Secret Sales Prior Art Under The AIA?
Jun
3
2012
Five Traps for the Unwary Licensee Sills Cummis & Gross P.C.
Jun
7
2014
Dietary Supplement Health and Education Act (DSHEA) – 20 Years Later – The Good, The Bad And The Ugly Sills Cummis & Gross P.C.
Jul
9
2019
Merck Sharp & Dohme Corp. v. Albrecht: The U.S. Supreme Court Weighs In On Preemption Sills Cummis & Gross P.C.
Apr
5
2023
D’Addario v. Johnson & Johnson – New Jersey Federal Court Addresses Express Pre-Emption In Class III Medical Device Case Sills Cummis & Gross P.C.
Nov
30
2018
In re Accutane Litigation: A Victory for Pharmaceutical Companies on Choice of Law and Label Warnings Sills Cummis & Gross P.C.
Aug
8
2014
Medical Devices: Parallel Claims Against Device Manufacturers post-Riegel? Sills Cummis & Gross P.C.
Jul
25
2019
Weeding through the NJ Medical Marijuana Law Amendments: What You Need to Know Sills Cummis & Gross P.C.
Apr
21
2021
New Jersey Appellate Division Finds that Evidence of 510(k) Clearance Cannot be Categorically Excluded in Medical Device Product Liability Cases Sills Cummis & Gross P.C.
May
2
2020
Re-Imagining the Shopping Center Post-COVID: Zoning Changes Needed to Accommodate Store Features No Longer Deemed Convenience Amenities Sills Cummis & Gross P.C.
Mar
4
2020
Federal Preemption in the Wake of Albrecht: The U.S. Supreme Court Unexpectedly Levels the Playing Field Sills Cummis & Gross P.C.
 

NLR Logo

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up to receive our free e-Newsbulletins

 

Sign Up for e-NewsBulletins